EASY BIO,Inc. (353810.KQ)
KRW 4570.0
(0.44%)
KRW 4570.0
(0.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 105.86 Billion KRW | 0.83% |
| 2022 | 104.99 Billion KRW | 45.27% |
| 2021 | 72.27 Billion KRW | 29.57% |
| 2020 | 55.78 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 187.56 Billion KRW | 77.17% |
| 2024 Q2 | 263.81 Billion KRW | 40.65% |
| 2023 Q2 | 97.98 Billion KRW | -13.66% |
| 2023 FY | 105.86 Billion KRW | 0.83% |
| 2023 Q4 | 105.86 Billion KRW | -8.92% |
| 2023 Q3 | 116.23 Billion KRW | 18.63% |
| 2023 Q1 | 113.49 Billion KRW | 8.09% |
| 2022 Q1 | 77.92 Billion KRW | 7.81% |
| 2022 FY | 104.99 Billion KRW | 45.27% |
| 2022 Q4 | 104.99 Billion KRW | -21.11% |
| 2022 Q3 | 133.09 Billion KRW | 25.49% |
| 2022 Q2 | 106.05 Billion KRW | 36.1% |
| 2021 Q4 | 72.27 Billion KRW | -11.9% |
| 2021 Q3 | 82.04 Billion KRW | 17.09% |
| 2021 Q2 | 70.06 Billion KRW | 10.09% |
| 2021 FY | 72.27 Billion KRW | 29.57% |
| 2021 Q1 | 63.64 Billion KRW | 14.09% |
| 2020 Q3 | 52.49 Billion KRW | 0.02% |
| 2020 Q4 | 55.78 Billion KRW | 6.25% |
| 2020 Q2 | 52.48 Billion KRW | 0.0% |
| 2020 FY | 55.78 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 37.531% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -5530.23% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -39.879% |
| Bioneer Corporation | 80.61 Billion KRW | -31.334% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -429.695% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 22.004% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -8.225% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -43.926% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 90.099% |
| Medy-Tox Inc. | 137.14 Billion KRW | 22.803% |
| Peptron, Inc. | 16.36 Billion KRW | -546.765% |
| Amicogen, Inc. | 248.12 Billion KRW | 57.332% |
| Genexine, Inc. | 79.68 Billion KRW | -32.862% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -261.623% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -156.459% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 2.207% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -44.854% |
| SillaJen, Inc. | 19.4 Billion KRW | -445.689% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 40.886% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -101.697% |
| Genomictree Inc. | 7.81 Billion KRW | -1255.16% |
| MedPacto, Inc. | 9.56 Billion KRW | -1006.751% |
| D&D Pharmatech | 23.98 Billion KRW | -341.383% |
| GI Innovation, Inc. | 9.63 Billion KRW | -998.656% |